Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00346749
Status:
TERMINATED
Last Update Posted:
2016-10-28
First Post:
2006-06-28
Brief Title:
ADVAIR DISKUS Fluticasone PropionateSalmeterol Inhaler Versus SEREVENT DISKUS Salmeterol Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease ADVAIR DISKUS and SEREVENT DISKUS Inhalers Are Trademarks of the GSK Group of Companies
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-Blind Parallel-Group 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone PropionateSalmeterol DISKUS 25050mcg BID Compared With Salmeterol DISKUS 50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease COPD
Status:
TERMINATED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated due to difficulties with finding sites and subjects willing to participate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the effect of two medicines on COPD Chronic Obstructive Pulmonary Disease The study will last 12 weeks At the end of 12 weeks of treatment subjects will stop the study medicines for 2 weeks The study will involve 6 visits to the clinic Subjects who elect to undergo bronchoalveolar lavage BAL procedures will have 8 study visits Subjects will give sputum blood and in some cases BAL samples Subjects will have breathing tests and will complete diary cards during the study All study medicines and examinations will be given at no cost to the study subjects Both medicines used in this study have been approved by the US FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None